203 stories across all digests
Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
Verdiva Bio will present two posters at ADA 2026 on its obesity pipeline: VRB-103, a once-weekly oral amylin-receptor-selective analog, and VRB-104, a unimolecular GLP-1 plus amylin co-agonist. The preclinical data extend the amylin and oral-peptide push from a well-funded newer entrant, as the obesity field broadens beyond incretin monotherapy toward amylin-based and oral approaches.
A study from Christian Heinis's lab, published June 1 in Nature Chemical Biology, screened a library of 15,360 random cyclic peptides for the rare ability to cross cell membranes, then refined a lead (Peptide 30, 890.6 daltons) that blocked the intracellular Keap1-Nrf2 interaction in living cells. By engineering lower charge, fewer hydrogen-bond donors, and smaller polar surface area, the approach reaches targets inside cells without starting from a known ligand, a route toward peptide drugs that can be taken orally.
A STAT and Undark investigation, supported by the Pulitzer Center and widely republished around June 1-2, examined the thin evidence behind BPC-157, the wound-healing peptide on the FDA's July 23-24 PCAC docket. Nearly all of the roughly 200 BPC-157 studies indexed on PubMed list Croatian researcher Predrag Sikiric or colleague Sven Seiwerth as an author, a concentration a Polish review team flagged as a confirmation-bias risk, and Sikiric's undisclosed conflicts include patents dating to 1989 and a CEO role at Diagen, which sells a patented version. Only three human studies have been published; STAT ran a June 1 follow-up carrying Sikiric's response to skeptics.
A study in the International Journal of Obesity compared semaglutide, tirzepatide, and retatrutide in MC4R-knockout mice, a model of the most common monogenic obesity. Over 21 days, mean body-weight reduction reached 31.6% with tirzepatide, 24.1% with retatrutide, and 19.7% with semaglutide, and tirzepatide also suppressed cumulative food intake most aggressively. All three improved plasma insulin, HOMA-IR, cholesterol, and liver-damage markers, suggesting incretin drugs can drive weight loss even when the POMC-MC4R satiety axis is disrupted.
A venom-peptide discovery system published in Pharmaceuticals (MDPI) in 2026 paired phage display with a machine-learning model that predicts mutation-tolerant residues, building a library from roughly 482 venom-derived scaffolds. Screened against CD47, DLL3, IL33, and P2X7R, the resulting VCX library yielded strong binders for all four targets. Venom peptides are stabilized by multiple disulfide bonds and naturally evolved to hit GPCRs and ion channels, giving them structural stability that conventional peptides often lack.
A review published May 19 in Drug Delivery and Translational Research analyzed nano-antimicrobial peptides (nano-AMPs) — antimicrobial peptides packaged into nanoparticle delivery systems — as a strategy to overcome the three barriers that have kept AMPs out of the clinic despite decades of promise: systemic toxicity, proteolytic instability, and manufacturing cost. The review focuses on activity against multidrug-resistant Gram-negative bacteria, the hardest antimicrobial-resistance target where the conventional-antibiotic pipeline is thinnest. Nanoparticle encapsulation can shield AMPs from protease degradation, reduce off-target toxicity by controlling release, and improve tissue targeting. The piece joins the broader 2026 AMP research wave — AI-designed peptides (ProteoGPT, CAMPER), generative-AI discovery in Nature Microbiology, and ancient-microbiome AMP mining — that is collectively maturing the antimicrobial peptide field toward clinical viability against the ESKAPE pathogens responsible for most drug-resistant infections.
A separate ASCO 2026 analysis examined outcomes in patients with breast cancer and co-existing obesity or type 2 diabetes who received GLP-1 receptor agonists — adding breast-cancer-specific depth to the broader GLP-1-and-cancer signal that ran through the meeting. The analysis sits alongside Abstract 3143 (the 12,112-patient study showing 38-50% lower metastatic progression across four obesity-related cancers, with breast cancer at 10% vs 20% metastasis on GLP-1 vs gliptin) and the Roswell Park aggressive-breast-cancer analysis. The consistent theme across the ASCO 2026 GLP-1 oncology slate: in obesity-related and metabolically-driven cancers, GLP-1 therapy appears associated with better outcomes, with the strongest and most mechanistically interpretable signal in breast cancer where high tumor GLP-1 receptor expression tracked with 45% lower mortality. Adverse-event rates matched the comparator groups with no increase in pancreatitis or other GLP-1-associated concerns in the cancer setting. The data is observational and not yet RCT-grade, but the breast-cancer consistency across multiple independent analyses strengthens the case for prospective study.
A Nature Microbiology paper (published May 22) reported a generative artificial-intelligence approach for discovering antimicrobial peptides against multidrug-resistant bacteria. The method uses transfer learning to give large language models domain-specific knowledge for high-throughput mining and generation of novel AMP candidates. The work joins the 2026 AI-AMP wave — ProteoGPT's 94.4% hit rate, the CAMPER mechanistic-AI MRSA platform, ancient-microbiome AMP mining, and the May 19 nano-AMP delivery review — that is collectively moving the antimicrobial peptide field from computational prediction toward clinical candidates. The convergence matters because antimicrobial resistance is projected to cause up to 10 million deaths annually by 2050, and the conventional small-molecule antibiotic pipeline has thinned to the point where membrane-targeting peptides with low resistance-development propensity are among the most credible near-term alternatives. The generative-AI design stack plus nanoparticle delivery addresses the two historical AMP bottlenecks — discovery throughput and the toxicity/stability/manufacturing gap — in parallel.
Roswell Park Comprehensive Cancer Center will present an analysis at ASCO 2026 (May 29-June 2 Chicago) by Dr. Zunairah Shah on the effects of GLP-1 receptor agonists in aggressive breast cancer. The real-world study examines whether GLP-1 therapy — widely used for glucose control and weight loss — confers additional benefit in high-risk breast cancer outcomes. The analysis joins the broader ASCO 2026 GLP-1 oncology slate, which includes Abstract 3143 (the 12,112-patient analysis showing 38-50% lower metastatic progression across four obesity-related cancers, with breast cancer showing 10% vs 20% metastasis on GLP-1 vs gliptin and 45% lower mortality with high tumor GLP-1R expression). Roswell Park also presented a companion real-world analysis on protein-energy malnutrition outcomes in metastatic TNBC (Abstract 1135). The GLP-1-and-cancer signal is one of the most-watched emerging themes at ASCO 2026, expanding the GLP-1 indication conversation beyond cardiometabolic disease.
A real-world data analysis previewed at ASCO's May 26 embargoed press briefing compared GLP-1 receptor agonists against DPP-4 inhibitors (gliptins) across 12,112 patients with seven obesity-related cancers. For four of the seven — lung, breast, colorectal, and liver — patients on GLP-1s were 38% to 50% less likely to progress to stage IV cancer than patients on gliptins. Specific metastasis rates: lung 10% (GLP-1) vs 22% (gliptin), breast 10% vs 20%, colorectal 13% vs 22%, liver 19% vs 28%. High tumor GLP-1 receptor expression was associated with a 33% lower risk of death across all seven cancer types; the association was particularly strong in breast cancer (45% lower mortality). The data reframes GLP-1 therapy as a candidate cancer-prevention modality alongside the established cardiometabolic indications. Abstract 3143 will be presented at the May 29-June 2 ASCO Annual Meeting in Chicago.
Bulevirtide's mechanism reveals why an entry inhibitor succeeded where small-molecule antivirals didn't. HDV is an obligate parasite of HBV — the delta virus uses the HBV envelope to assemble its virions and the HBV-derived large surface protein to enter hepatocytes via the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocyte cell membranes. Existing HBV antiviral nucleoside/nucleotide analogs (entecavir, tenofovir) suppress HBV replication but don't clear circulating HBsAg or interrupt the HDV entry cycle. Bulevirtide's 47-amino acid sequence — derived from the HBV pre-S1 domain — binds NTCP competitively and blocks both HDV and HBV entry. Real-world EU experience since 2020 shows roughly 50-60% of HDV patients achieve undetectable HDV RNA after 96 weeks of treatment, with a favorable safety profile dominated by injection-site reactions. The US approval expands access for an estimated 75,000-100,000 US patients with chronic HDV, most of whom were previously treated empirically with off-label interferon alfa with poor tolerability.
Researchers at Anglia Ruskin University published a systematic review and meta-analysis in Cardiovascular Diabetology - Endocrinology Reports on May 20 covering long-term cardiovascular outcomes for glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations. The review aggregated data from more than 90,000 participants across large international clinical trials. The headline finding: GLP-1 receptor agonists significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term in patients with established cardiovascular disease and high cardiovascular risk. The review extends the SELECT 20% MACE-reduction signal to the broader high-risk-CV population and joins the established cardiovascular-outcomes evidence base alongside the LEADER (liraglutide), SUSTAIN-6 (semaglutide), and STEP-HFpEF (semaglutide in heart failure) trial readouts. The Anglia Ruskin synthesis is the broadest evidence aggregation to date — directly relevant to the Medicare GLP-1 Bridge that begins July 1, 2026.
A 2026 Nature Communications paper introduced AMPLiT — a tool for screening antimicrobial peptide candidates in metagenomic datasets — and applied it to human coprolite metagenomes (ancient stool samples). The team identified candidate AMPs from extinct gut-microbiome lineages that have functional activity against modern multidrug-resistant pathogens. The approach extends the AMP-discovery search space from contemporary microbial sequences to the much-larger reservoir of evolutionary AMPs encoded in ancient host-microbiome assemblies preserved in archaeological samples. The strategy joins the broader 2026 AI-AMP wave (ProteoGPT, CAMPER, the AI-driven AMP characterization paper in Scientific Reports) as an alternative source of novel chemistry against ESKAPE pathogens. The work positions ancient-DNA-based AMP discovery as a credible track alongside computational design.
A Nature Communications paper from a Texas A&M Health team published May 19 reported the engineering of genetically encoded calcium release-activated calcium channel (CRAC) inhibitory binders called CRABs — peptide inhibitors derived from the ORAI C-terminal tail that selectively interfere with STIM1-ORAI coupling. The plasma-membrane-anchored CRAB variant potently inhibits calcium influx and downstream NFAT signaling. The platform spans optogenetic (Opto-CRAB) and chemogenetic (Chemo-CRAB) variants for graded, real-time control of CRAC activity. In a zebrafish Stormorken syndrome model, CRABs rescued thrombocyte progenitor production. The therapeutic implication: a peptide-based adjustable brake on T-cell calcium signaling that could enable safer, more controllable immune cell therapies — CAR-T cytokine release moderation, autoimmune T-cell quenching, transplantation tolerance induction.
A Journal of Peptide Science paper reported a novel four-amino-acid peptide WDGL (Trp-Asp-Gly-Leu) derived from Ulva prolifera — the green algae species responsible for major coastal blooms in East Asia. The peptide was identified through virtual screening of marine-derived peptide libraries, binds Keap1 at key residues, and activates the Nrf2 antioxidant pathway in cellular oxidative-stress models. In vitro pharmacokinetic profiling showed favorable properties for further development. The mechanistic rationale: Keap1-Nrf2 activation drives expression of antioxidant response element (ARE)-regulated genes including superoxide dismutase, catalase, and glutathione peroxidase, reducing reactive oxygen species (ROS) and oxidative damage. The WDGL work joins a small but growing literature on tetrapeptides as drug-like scaffolds — Aivocode's CAQK brain-injury tetrapeptide being the other May 2026 example. Marine-derived AMP and bioactive peptide discovery remains an underexplored chemistry frontier.
A Science magazine feature published May 8 highlighted iRGD — a 9-amino-acid tumor-penetrating peptide originally identified by Erkki Ruoslahti's group at Sanford Burnham Prebys — as a candidate to improve delivery of cancer chemotherapy and immunotherapy into solid tumors. iRGD binds α-v integrins overexpressed on tumor vasculature, then is proteolytically processed to expose a cryptic CendR motif that engages neuropilin-1 and triggers a transient tumor-vascular permeability burst. Co-administered with chemotherapy, iRGD increases drug penetration into the tumor without covalent conjugation. Early clinical studies in pancreatic cancer combining iRGD with nab-paclitaxel and gemcitabine showed improved tumor response and progression-free survival; later-stage development continues through DrugCendR (the Ruoslahti lab spinout) and academic-industrial partnerships. The Science piece frames iRGD as a complementary technology to antibody-drug conjugates and peptide-drug conjugates — a co-administered delivery enhancer rather than a covalent payload carrier.
Fadi Shehadeh, Biswajit Mishra and collaborators published CAMPER (Constraint-driven AMP Engineering with Ranking) in Nature Communications 2026, integrating machine learning with mechanistic biological features to design peptides that target MRSA persister cells. The lead candidate, WP-CAMPER1, kills S. aureus MW2 at a minimal inhibitory concentration of 4 µg/mL. A 2% topical formulation reduced bacterial burden 2.5 log10 in a murine prophylactic skin infection model; the D-enantiomer WP-CAMPER1-d achieved 1.37 log10 reduction in established biofilm infections.
A Nature Communications paper details crystalline mesoporous frameworks built from amphiphilic collagen-mimetic peptides (aCMPs) — charge-segregated collagen-mimetic sequences modified with lipid tails at their N-termini. Hydrophobic and electrostatic interactions drive 3D porous architectures whose lattice packing tracks with lipid-tail length (C12, C10, C8); shortening to C6 flips assembly into nanosheets. The work expands peptide-based biomaterials beyond the triple helix and offers a programmable scaffold platform for drug delivery and tissue engineering.